董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gary J. Bridger | 男 | Independent Director | 62 | 未披露 | 未持股 | 2025-09-16 |
| Murray W. Stewart | 男 | Independent Director | 64 | 未披露 | 未持股 | 2025-09-16 |
| Adam Raymond Craig | 男 | Executive Chairman and Principal Executive Officer | 59 | 未披露 | 未持股 | 2025-09-16 |
| Francoise de Craecker | -- | Independent Director | -- | 未披露 | 未持股 | 2025-09-16 |
| Michael S. Wyzga | 男 | Lead Independent Director | 70 | 292.73万美元 | 未持股 | 2025-09-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David H. Kirske | 男 | Chief Financial Officer, Secretary and Principal Accounting Officer | 70 | 未披露 | 未持股 | 2025-09-16 |
| Adam Raymond Craig | 男 | Executive Chairman and Principal Executive Officer | 59 | 未披露 | 未持股 | 2025-09-16 |
| John Volpone | 男 | President and Chief Operating Officer | 50 | 未披露 | 未持股 | 2025-09-16 |
董事简历
中英对照 | 中文 | 英文- Gary J. Bridger
-
GaryJ.Bridger自2019年5月以来一直担任我们的董事会成员。Bridger博士自2018年10月起也担任X4Pharmaceuticals，Inc.董事会成员。2015年2月至2017年12月，Bridger博士曾担任生物制药公司Xenon PharmaceuticalsInc.的顾问，此前曾于2013年1月至2015年2月担任研究与开发的执行Vice President。Bridger从2013年10月到2015年10月担任Five Corners Capital Inc.总经理。Bridger从2010年6月到2012年6月担任Venture West Capital Management（一家风险投资公司）风险合伙人。从2006年11月到2007年12月，Bridger博士担任生物技术公司健赞公司（Sanofi，S.A.）研究与开发的高级副总裁，该公司于1996年6月被赛诺菲公司（Sanofi，S.A.）收购，Bridger博士共同创立了生物制药公司AnorMed Inc.，2000年至2006年11月被Genzyme收购，担任研究与开发Vice President和首席科学官。Bridger博士自2013年以来一直在Aquinox Pharmaceuticals，Inc.的董事会任职。Bridger博士拥有曼彻斯特科技大学（University of Manchester Institute of Science and Technology）的有机化学博士学位。
Gary J. Bridger has served as a member of board of directors since May 2019. Dr. Bridger has also served as a member of the board of directors of X4 Pharmaceuticals, Inc. since October 2018. From February 2015 to December 2017 Dr. Bridger served as a consultant to Xenon Pharmaceuticals Inc., a biopharmaceutical company, where he previously served as the Executive Vice President of Research and Development from January 2013 to February 2015. From October 2013 to October 2015 Dr. Bridger served as a Managing Director at Five Corners Capital Inc. From June 2010 to June 2012 Dr. Bridger served as a venture partner at Venture West Capital Management, a venture capital firm. From November 2006 to December 2007 Dr. Bridger served as Senior Vice President of Research and Development of Genzyme Corporation, a biotechnology company, which was acquired by Sanofi, S.A. In June 1996 Dr. Bridger co-founded AnorMED Inc., a biopharmaceutical company, and was its Vice President of Research and Development and Chief Scientific Officer from 2000 until its acquisition by Genzyme in November 2006. Dr. Bridger has served on the board of directors of Aquinox Pharmaceuticals, Inc. since 2013. Dr. Bridger holds a Ph.D. in Organic Chemistry from the University of Manchester Institute of Science and Technology. - GaryJ.Bridger自2019年5月以来一直担任我们的董事会成员。Bridger博士自2018年10月起也担任X4Pharmaceuticals，Inc.董事会成员。2015年2月至2017年12月，Bridger博士曾担任生物制药公司Xenon PharmaceuticalsInc.的顾问，此前曾于2013年1月至2015年2月担任研究与开发的执行Vice President。Bridger从2013年10月到2015年10月担任Five Corners Capital Inc.总经理。Bridger从2010年6月到2012年6月担任Venture West Capital Management（一家风险投资公司）风险合伙人。从2006年11月到2007年12月，Bridger博士担任生物技术公司健赞公司（Sanofi，S.A.）研究与开发的高级副总裁，该公司于1996年6月被赛诺菲公司（Sanofi，S.A.）收购，Bridger博士共同创立了生物制药公司AnorMed Inc.，2000年至2006年11月被Genzyme收购，担任研究与开发Vice President和首席科学官。Bridger博士自2013年以来一直在Aquinox Pharmaceuticals，Inc.的董事会任职。Bridger博士拥有曼彻斯特科技大学（University of Manchester Institute of Science and Technology）的有机化学博士学位。
- Gary J. Bridger has served as a member of board of directors since May 2019. Dr. Bridger has also served as a member of the board of directors of X4 Pharmaceuticals, Inc. since October 2018. From February 2015 to December 2017 Dr. Bridger served as a consultant to Xenon Pharmaceuticals Inc., a biopharmaceutical company, where he previously served as the Executive Vice President of Research and Development from January 2013 to February 2015. From October 2013 to October 2015 Dr. Bridger served as a Managing Director at Five Corners Capital Inc. From June 2010 to June 2012 Dr. Bridger served as a venture partner at Venture West Capital Management, a venture capital firm. From November 2006 to December 2007 Dr. Bridger served as Senior Vice President of Research and Development of Genzyme Corporation, a biotechnology company, which was acquired by Sanofi, S.A. In June 1996 Dr. Bridger co-founded AnorMED Inc., a biopharmaceutical company, and was its Vice President of Research and Development and Chief Scientific Officer from 2000 until its acquisition by Genzyme in November 2006. Dr. Bridger has served on the board of directors of Aquinox Pharmaceuticals, Inc. since 2013. Dr. Bridger holds a Ph.D. in Organic Chemistry from the University of Manchester Institute of Science and Technology.
- Murray W. Stewart
-
MurrayW.Stewart自2019年3月以来一直担任我们的董事会成员。Stewart博士自2018年10月起担任生物制药公司RhythmPharmaceuticals，Inc.的首席医疗官，该公司专注于开发和商业化治疗罕见的肥胖性遗传疾病的疗法。2017年11月至2018年10月，他曾担任生物制药公司Novelion TherapeuticsInc.的研发主管，该公司专注于为罕见病患者开发新的护理标准，他在该公司负责监督针对罕见代谢疾病的两种上市产品Juxtapid®；和Myalept®；的全球医疗事务。在此之前，Stewart博士于2014年4月至2017年11月担任葛兰素史克GSK的首席医疗官，负责疫苗，制药和消费者业务部门的全球患者福祉。在GSK的18年职业生涯中，Stewart博士担任过多个研究与开发领导职务，包括制药业务首席医疗官、生物制药部门临床主管以及代谢和心血管疾病治疗领域主管。任职GSK公司之前，他曾担任英国纽卡斯尔泰恩河畔糖尿病中心的顾问医生和荣誉高级讲师。Stewart博士拥有南安普顿医学院的医学博士学位，也是皇家内科医学院的院士。
Murray W. Stewart has served as a member of board of directors since March 2019. Dr. Stewart has served as Chief Medical Officer of Rhythm Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing therapies for the treatment of rare genetic disorders of obesity, since October 2018. He previously served as Head of R&D for Novelion Therapeutics Inc., a biopharmaceutical company focused on developing new standards of care for individuals living with rare disease, where he oversaw global medical affairs for Juxtapid and Myalept, two marketed products for rare metabolic diseases, from November 2017 to October 2018. Prior to that, Dr. Stewart was Chief Medical Officer at GlaxoSmithKline GSK, with global responsibility for patient well-being across the vaccine, pharmaceutical, and consumer business units, from April 2014 to November 2017. During his 18-year career at GSK, Dr. Stewart held multiple research and development leadership roles, including Chief Medical Officer for the pharmaceutical business, Clinical Head of the Biopharma Unit, and Therapy Area Head for metabolic and cardiovascular diseases. Prior to his tenure with GSK, he worked as a consultant physician and honorary senior lecturer at the Diabetes Center in Newcastle upon Tyne in the U.K. Dr. Stewart holds an M.D. from Southampton Medical School and is a Fellow of the Royal College of Physicians. - MurrayW.Stewart自2019年3月以来一直担任我们的董事会成员。Stewart博士自2018年10月起担任生物制药公司RhythmPharmaceuticals，Inc.的首席医疗官，该公司专注于开发和商业化治疗罕见的肥胖性遗传疾病的疗法。2017年11月至2018年10月，他曾担任生物制药公司Novelion TherapeuticsInc.的研发主管，该公司专注于为罕见病患者开发新的护理标准，他在该公司负责监督针对罕见代谢疾病的两种上市产品Juxtapid®；和Myalept®；的全球医疗事务。在此之前，Stewart博士于2014年4月至2017年11月担任葛兰素史克GSK的首席医疗官，负责疫苗，制药和消费者业务部门的全球患者福祉。在GSK的18年职业生涯中，Stewart博士担任过多个研究与开发领导职务，包括制药业务首席医疗官、生物制药部门临床主管以及代谢和心血管疾病治疗领域主管。任职GSK公司之前，他曾担任英国纽卡斯尔泰恩河畔糖尿病中心的顾问医生和荣誉高级讲师。Stewart博士拥有南安普顿医学院的医学博士学位，也是皇家内科医学院的院士。
- Murray W. Stewart has served as a member of board of directors since March 2019. Dr. Stewart has served as Chief Medical Officer of Rhythm Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing therapies for the treatment of rare genetic disorders of obesity, since October 2018. He previously served as Head of R&D for Novelion Therapeutics Inc., a biopharmaceutical company focused on developing new standards of care for individuals living with rare disease, where he oversaw global medical affairs for Juxtapid and Myalept, two marketed products for rare metabolic diseases, from November 2017 to October 2018. Prior to that, Dr. Stewart was Chief Medical Officer at GlaxoSmithKline GSK, with global responsibility for patient well-being across the vaccine, pharmaceutical, and consumer business units, from April 2014 to November 2017. During his 18-year career at GSK, Dr. Stewart held multiple research and development leadership roles, including Chief Medical Officer for the pharmaceutical business, Clinical Head of the Biopharma Unit, and Therapy Area Head for metabolic and cardiovascular diseases. Prior to his tenure with GSK, he worked as a consultant physician and honorary senior lecturer at the Diabetes Center in Newcastle upon Tyne in the U.K. Dr. Stewart holds an M.D. from Southampton Medical School and is a Fellow of the Royal College of Physicians.
- Adam Raymond Craig
-
Adam Raymond Craig，最近于2024年8月至2025年3月担任Stratus Therapeutics，Inc.（“Stratus Therapeutics”，原名Garuda Therapeutics，Inc.）的临时总裁兼首席执行官。他还曾担任CTI BioPharma Corp.（“CTI BioPharma”）的总裁、首席执行官兼临时首席医疗官，并于2017年3月至2023年6月期间担任其董事会成员。他是一名医生和经验丰富的生物制药行业领导者，在企业战略运营和治理、投资者关系和融资；美国和欧盟监管参与；以及医疗事务和血液学和肿瘤学研究方面拥有广泛的专业知识。在加入CTI BioPharma之前，Craig博士自2016年起担任独立顾问，为CTI BioPharma和其他血液学/肿瘤学生物技术公司提供战略和运营建议及支持。在咨询之前，Craig博士曾于2012年至2016年担任Sunesis Pharmaceuticals的首席医疗官和开发执行副总裁，该公司是一家生物制药公司，开发用于治疗血液和实体癌的新型靶向抑制剂。从2008年到2012年，克雷格博士担任Chemgenex Pharmaceuticals Ltd的首席医疗官和高级副总裁，该公司是一家生物技术公司，于2011年被Cephalon/Teva Pharmaceuticals收购。他还曾担任德克萨斯州癌症预防研究所的产品开发审评员。自2024年8月以来，克雷格博士一直是Stratus Therapeutics的董事会成员。克雷格博士在伦敦大学查林克罗斯和威斯敏斯特医学院获得医学学位，在英国利兹大学获得分子肿瘤学博士学位，在开放大学商学院（英国）获得工商管理硕士学位。Craig博士完成了儿科、新生儿科和儿科肿瘤学的研究生培训，并且是皇家内科医学院（伦敦）和皇家儿科和儿童健康学院的成员。
Adam Raymond Craig,most recently served as the Interim President and Chief Executive Officer of Stratus Therapeutics, Inc. ("Stratus Therapeutics," formerly known as Garuda Therapeutics, Inc.) from August 2024 until March 2025. He also served as President, Chief Executive Officer and Interim Chief Medical Officer of CTI BioPharma Corp. ("CTI BioPharma") and as a member of its board of directors from March 2017 until June 2023. He is a physician and experienced biopharmaceutical industry leader with extensive expertise in corporate strategic operations and governance, investor relations and financing; U.S. and EU regulatory engagement; and medical affairs and hematology and oncology research. Prior to CTI BioPharma, Dr. Craig worked as an independent consultant providing strategic and operational advice and support to CTI BioPharma and other hematology/oncology biotechnology companies since 2016. Prior to consulting, Dr. Craig was Chief Medical Officer and Executive Vice President of Development of Sunesis Pharmaceuticals, a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers, from 2012 to 2016. From 2008 to 2012, Dr. Craig was Chief Medical Officer and Senior Vice President of Chemgenex Pharmaceuticals Ltd, a biotechnology company which was acquired by Cephalon/Teva Pharmaceuticals in 2011. He also served as a Product Development Reviewer for the Cancer Prevention Research Institute of Texas. Dr. Craig has been a member of the board of directors of Stratus Therapeutics since August 2024. Dr. Craig earned his Medical Degree from Charing Cross and Westminster Medical School, University of London, a Ph.D. in Molecular Oncology from Leeds University in the U.K. and an M.B.A. from The Open University Business School (U.K.). Dr. Craig completed post-graduate training in Paediatrics, Neonatology and Paediatric Oncology and is a Member of both the Royal College of Physicians (London) and the Royal College of Paediatrics and Child Health. - Adam Raymond Craig，最近于2024年8月至2025年3月担任Stratus Therapeutics，Inc.（“Stratus Therapeutics”，原名Garuda Therapeutics，Inc.）的临时总裁兼首席执行官。他还曾担任CTI BioPharma Corp.（“CTI BioPharma”）的总裁、首席执行官兼临时首席医疗官，并于2017年3月至2023年6月期间担任其董事会成员。他是一名医生和经验丰富的生物制药行业领导者，在企业战略运营和治理、投资者关系和融资；美国和欧盟监管参与；以及医疗事务和血液学和肿瘤学研究方面拥有广泛的专业知识。在加入CTI BioPharma之前，Craig博士自2016年起担任独立顾问，为CTI BioPharma和其他血液学/肿瘤学生物技术公司提供战略和运营建议及支持。在咨询之前，Craig博士曾于2012年至2016年担任Sunesis Pharmaceuticals的首席医疗官和开发执行副总裁，该公司是一家生物制药公司，开发用于治疗血液和实体癌的新型靶向抑制剂。从2008年到2012年，克雷格博士担任Chemgenex Pharmaceuticals Ltd的首席医疗官和高级副总裁，该公司是一家生物技术公司，于2011年被Cephalon/Teva Pharmaceuticals收购。他还曾担任德克萨斯州癌症预防研究所的产品开发审评员。自2024年8月以来，克雷格博士一直是Stratus Therapeutics的董事会成员。克雷格博士在伦敦大学查林克罗斯和威斯敏斯特医学院获得医学学位，在英国利兹大学获得分子肿瘤学博士学位，在开放大学商学院（英国）获得工商管理硕士学位。Craig博士完成了儿科、新生儿科和儿科肿瘤学的研究生培训，并且是皇家内科医学院（伦敦）和皇家儿科和儿童健康学院的成员。
- Adam Raymond Craig,most recently served as the Interim President and Chief Executive Officer of Stratus Therapeutics, Inc. ("Stratus Therapeutics," formerly known as Garuda Therapeutics, Inc.) from August 2024 until March 2025. He also served as President, Chief Executive Officer and Interim Chief Medical Officer of CTI BioPharma Corp. ("CTI BioPharma") and as a member of its board of directors from March 2017 until June 2023. He is a physician and experienced biopharmaceutical industry leader with extensive expertise in corporate strategic operations and governance, investor relations and financing; U.S. and EU regulatory engagement; and medical affairs and hematology and oncology research. Prior to CTI BioPharma, Dr. Craig worked as an independent consultant providing strategic and operational advice and support to CTI BioPharma and other hematology/oncology biotechnology companies since 2016. Prior to consulting, Dr. Craig was Chief Medical Officer and Executive Vice President of Development of Sunesis Pharmaceuticals, a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers, from 2012 to 2016. From 2008 to 2012, Dr. Craig was Chief Medical Officer and Senior Vice President of Chemgenex Pharmaceuticals Ltd, a biotechnology company which was acquired by Cephalon/Teva Pharmaceuticals in 2011. He also served as a Product Development Reviewer for the Cancer Prevention Research Institute of Texas. Dr. Craig has been a member of the board of directors of Stratus Therapeutics since August 2024. Dr. Craig earned his Medical Degree from Charing Cross and Westminster Medical School, University of London, a Ph.D. in Molecular Oncology from Leeds University in the U.K. and an M.B.A. from The Open University Business School (U.K.). Dr. Craig completed post-graduate training in Paediatrics, Neonatology and Paediatric Oncology and is a Member of both the Royal College of Physicians (London) and the Royal College of Paediatrics and Child Health.
- Francoise de Craecker
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Michael S. Wyzga
-
Michael S. Wyzga，自2019年3月合并完成后担任董事会成员。在合并之前，Wyzga先生自2018年7月起担任X4董事会主席。Wyzga先生目前是MSW Consulting Inc.的总裁。2011年12月至2013年11月，Wyzga先生在上市的生物制药公司Radius Health, Inc.担任总裁兼首席执行官和董事会成员。在此之前，Wyzga先生曾在全球生物技术上市公司健赞担任多个高级管理职位。Wyzga先生于1998年2月加入健赞，最近于2003年5月至2011年11月担任财务执行副总裁，并于1999年7月至2011年11月担任首席财务官。2014年2月至2018年12月，Wyzga先生担任上市生物制药公司Akebia Therapeutics, Inc.的董事会成员，同时也是薪酬委员会成员和审计委员会主席。自2015年2月起，Wyzga先生还担任医疗技术上市公司Exact Sciences Corporation的董事会成员。自2013年10月起至2019年4月Oncomed Pharmaceuticals, Inc.与Mereo BioPharma Group plc进行企业合并之前，Wyzga先生一直担任Oncomed Pharmaceuticals, Inc.的董事会成员，同时他还是审计委员会的成员。自2016年2月起，Wyzga先生还担任泛欧交易所上市生物制药公司GenSight Biologics S.A.的董事会主席。Wyzga先生此前还曾担任β胞核嘧啶制药的董事会成员，并于2014年6月起担任上市生物制药公司Prosensa Holding B.V。的监事会成员，直至2014年12月BioMarin Falcon B.V。收购Prosensa.他获得了普罗维登斯学院的工商管理硕士学位和萨福克大学的学士学位。
Michael S. Wyzga has served as a member of board of directors since the closing of the Merger in March 2019. Prior to the Merger, Mr. Wyzga served as Chairman of the X4 board of directors since July 2018. Mr. Wyzga is currently the President of MSW Consulting Inc., a strategic consulting group focused in the life sciences area. From December 2011 until November 2013 Mr. Wyzga served as President and Chief Executive Officer and a member of the board of directors of Radius Health, Inc., a publicly traded biopharmaceutical company. Prior to that, Mr. Wyzga served in various senior management positions at Genzyme Corporation, a publicly traded global biotechnology company. Mr. Wyzga joined Genzyme in February 1998 and most recently served as Executive Vice President, Finance from May 2003 until November 2011 and as chief financial officer from July 1999 until November 2011. From February 2014 to December 2018 Mr. Wyzga served as a member of the board of directors of Akebia Therapeutics, Inc., a publicly traded biopharmaceutical company, where he was also a member of the compensation committee and chair of the audit committee. Since February 2015 Mr. Wyzga has also served as a member of the board of directors of Exact Sciences Corporation, a publicly traded medical technology company, where he is also a member of the audit and compensation committees. From October 2013 until Oncomed Pharmaceuticals, Inc.'s business combination with Mereo BioPharma Group plc in April 2019 Mr. Wyzga served as a member of the board of directors of Oncomed Pharmaceuticals, Inc., where he was also a member of the audit committee. Since February 2016 Mr. Wyzga has also served as Chairman of the board of directors of GenSight Biologics S.A., a Euronext traded biopharmaceutical company. Mr. Wyzga also previously served as a member of the board of directors of Idenix Pharmaceuticals, Inc., a publicly traded biotechnology company that was acquired by Merck in August 2014 where he also served as the chair of the audit committee and a member of the compensation committee, and as a member of the Supervisory Board of Prosensa Holding B.V., a publicly traded biopharmaceutical company, from June 2014 until the Prosensa acquisition by BioMarin Falcon B.V. in December 2014. He received an M.B.A. from Providence College and a B.S. from Suffolk University. - Michael S. Wyzga，自2019年3月合并完成后担任董事会成员。在合并之前，Wyzga先生自2018年7月起担任X4董事会主席。Wyzga先生目前是MSW Consulting Inc.的总裁。2011年12月至2013年11月，Wyzga先生在上市的生物制药公司Radius Health, Inc.担任总裁兼首席执行官和董事会成员。在此之前，Wyzga先生曾在全球生物技术上市公司健赞担任多个高级管理职位。Wyzga先生于1998年2月加入健赞，最近于2003年5月至2011年11月担任财务执行副总裁，并于1999年7月至2011年11月担任首席财务官。2014年2月至2018年12月，Wyzga先生担任上市生物制药公司Akebia Therapeutics, Inc.的董事会成员，同时也是薪酬委员会成员和审计委员会主席。自2015年2月起，Wyzga先生还担任医疗技术上市公司Exact Sciences Corporation的董事会成员。自2013年10月起至2019年4月Oncomed Pharmaceuticals, Inc.与Mereo BioPharma Group plc进行企业合并之前，Wyzga先生一直担任Oncomed Pharmaceuticals, Inc.的董事会成员，同时他还是审计委员会的成员。自2016年2月起，Wyzga先生还担任泛欧交易所上市生物制药公司GenSight Biologics S.A.的董事会主席。Wyzga先生此前还曾担任β胞核嘧啶制药的董事会成员，并于2014年6月起担任上市生物制药公司Prosensa Holding B.V。的监事会成员，直至2014年12月BioMarin Falcon B.V。收购Prosensa.他获得了普罗维登斯学院的工商管理硕士学位和萨福克大学的学士学位。
- Michael S. Wyzga has served as a member of board of directors since the closing of the Merger in March 2019. Prior to the Merger, Mr. Wyzga served as Chairman of the X4 board of directors since July 2018. Mr. Wyzga is currently the President of MSW Consulting Inc., a strategic consulting group focused in the life sciences area. From December 2011 until November 2013 Mr. Wyzga served as President and Chief Executive Officer and a member of the board of directors of Radius Health, Inc., a publicly traded biopharmaceutical company. Prior to that, Mr. Wyzga served in various senior management positions at Genzyme Corporation, a publicly traded global biotechnology company. Mr. Wyzga joined Genzyme in February 1998 and most recently served as Executive Vice President, Finance from May 2003 until November 2011 and as chief financial officer from July 1999 until November 2011. From February 2014 to December 2018 Mr. Wyzga served as a member of the board of directors of Akebia Therapeutics, Inc., a publicly traded biopharmaceutical company, where he was also a member of the compensation committee and chair of the audit committee. Since February 2015 Mr. Wyzga has also served as a member of the board of directors of Exact Sciences Corporation, a publicly traded medical technology company, where he is also a member of the audit and compensation committees. From October 2013 until Oncomed Pharmaceuticals, Inc.'s business combination with Mereo BioPharma Group plc in April 2019 Mr. Wyzga served as a member of the board of directors of Oncomed Pharmaceuticals, Inc., where he was also a member of the audit committee. Since February 2016 Mr. Wyzga has also served as Chairman of the board of directors of GenSight Biologics S.A., a Euronext traded biopharmaceutical company. Mr. Wyzga also previously served as a member of the board of directors of Idenix Pharmaceuticals, Inc., a publicly traded biotechnology company that was acquired by Merck in August 2014 where he also served as the chair of the audit committee and a member of the compensation committee, and as a member of the Supervisory Board of Prosensa Holding B.V., a publicly traded biopharmaceutical company, from June 2014 until the Prosensa acquisition by BioMarin Falcon B.V. in December 2014. He received an M.B.A. from Providence College and a B.S. from Suffolk University.
高管简历
中英对照 | 中文 | 英文- David H. Kirske
David H.Kirske于2017年9月首席财务官担任我们的执行Vice President。在此之前，他自2017年8月起担任我们的首席财务和会计官。Kirske先生领导我们的财务，会计和投资者关系团队。在被任命之前，Kirske先生自2013年1月起担任独立的首席财务官首席财务官顾问。Kirske先生的财务管理经验包括监督债务和股权的财务，会计，运营和资本化。在担任顾问之前，Kirske先生曾担任Helix Biomedix的Vice President和首席财务官，管理该公司的所有财务和行政活动。此前，他曾担任F-5Networks公司和Redhook Brewery公司的财务主管兼公司总会计师，在那里他曾管理公司和国际实体，以及领导和执行每个公司成功的首次公开募股的管理团队的一部分。职业生涯早期，他曾担任Cray Computer公司的控制职务。Kirske先生拥有University of Puget Sound的工商管理学士学位。
David H. Kirske,most recently served as the Chief Financial Officer of Stratus Therapeutics from September 2024 to May 2025. From August 2023 to September 2024, Mr. Kirske provided financial strategy for biotechnology companies as part of Madrona Financial Consulting. Prior to that, he served as CTI BioPharma's Executive Vice President, Chief Financial Officer from September 2017 until June 2023. He is a finance, accounting and investor relations leader for public and emerging growth private companies primarily in the biotechnology industry, as well as in technology and manufacturing. His financial management experience includes overseeing finance, accounting, operations and capitalization in debt and equity. Prior to CTI BioPharma, Mr. Kirske served as Vice President and Chief Financial Officer of Helix BioMedix where he managed all financial and administrative activities. Previously, he was the Treasurer and Corporate Controller for F-5 Networks and Redhook Brewery, where he managed corporate and international entities and was part of the management teams that led and executed each company's successful initial public offering. Earlier, he held a controllership position at Cray Computer. Mr. Kirske holds a B.A. in Business Administration from the University of Puget Sound.- David H.Kirske于2017年9月首席财务官担任我们的执行Vice President。在此之前，他自2017年8月起担任我们的首席财务和会计官。Kirske先生领导我们的财务，会计和投资者关系团队。在被任命之前，Kirske先生自2013年1月起担任独立的首席财务官首席财务官顾问。Kirske先生的财务管理经验包括监督债务和股权的财务，会计，运营和资本化。在担任顾问之前，Kirske先生曾担任Helix Biomedix的Vice President和首席财务官，管理该公司的所有财务和行政活动。此前，他曾担任F-5Networks公司和Redhook Brewery公司的财务主管兼公司总会计师，在那里他曾管理公司和国际实体，以及领导和执行每个公司成功的首次公开募股的管理团队的一部分。职业生涯早期，他曾担任Cray Computer公司的控制职务。Kirske先生拥有University of Puget Sound的工商管理学士学位。
- David H. Kirske,most recently served as the Chief Financial Officer of Stratus Therapeutics from September 2024 to May 2025. From August 2023 to September 2024, Mr. Kirske provided financial strategy for biotechnology companies as part of Madrona Financial Consulting. Prior to that, he served as CTI BioPharma's Executive Vice President, Chief Financial Officer from September 2017 until June 2023. He is a finance, accounting and investor relations leader for public and emerging growth private companies primarily in the biotechnology industry, as well as in technology and manufacturing. His financial management experience includes overseeing finance, accounting, operations and capitalization in debt and equity. Prior to CTI BioPharma, Mr. Kirske served as Vice President and Chief Financial Officer of Helix BioMedix where he managed all financial and administrative activities. Previously, he was the Treasurer and Corporate Controller for F-5 Networks and Redhook Brewery, where he managed corporate and international entities and was part of the management teams that led and executed each company's successful initial public offering. Earlier, he held a controllership position at Cray Computer. Mr. Kirske holds a B.A. in Business Administration from the University of Puget Sound.
- Adam Raymond Craig
Adam Raymond Craig，最近于2024年8月至2025年3月担任Stratus Therapeutics，Inc.（“Stratus Therapeutics”，原名Garuda Therapeutics，Inc.）的临时总裁兼首席执行官。他还曾担任CTI BioPharma Corp.（“CTI BioPharma”）的总裁、首席执行官兼临时首席医疗官，并于2017年3月至2023年6月期间担任其董事会成员。他是一名医生和经验丰富的生物制药行业领导者，在企业战略运营和治理、投资者关系和融资；美国和欧盟监管参与；以及医疗事务和血液学和肿瘤学研究方面拥有广泛的专业知识。在加入CTI BioPharma之前，Craig博士自2016年起担任独立顾问，为CTI BioPharma和其他血液学/肿瘤学生物技术公司提供战略和运营建议及支持。在咨询之前，Craig博士曾于2012年至2016年担任Sunesis Pharmaceuticals的首席医疗官和开发执行副总裁，该公司是一家生物制药公司，开发用于治疗血液和实体癌的新型靶向抑制剂。从2008年到2012年，克雷格博士担任Chemgenex Pharmaceuticals Ltd的首席医疗官和高级副总裁，该公司是一家生物技术公司，于2011年被Cephalon/Teva Pharmaceuticals收购。他还曾担任德克萨斯州癌症预防研究所的产品开发审评员。自2024年8月以来，克雷格博士一直是Stratus Therapeutics的董事会成员。克雷格博士在伦敦大学查林克罗斯和威斯敏斯特医学院获得医学学位，在英国利兹大学获得分子肿瘤学博士学位，在开放大学商学院（英国）获得工商管理硕士学位。Craig博士完成了儿科、新生儿科和儿科肿瘤学的研究生培训，并且是皇家内科医学院（伦敦）和皇家儿科和儿童健康学院的成员。
Adam Raymond Craig,most recently served as the Interim President and Chief Executive Officer of Stratus Therapeutics, Inc. ("Stratus Therapeutics," formerly known as Garuda Therapeutics, Inc.) from August 2024 until March 2025. He also served as President, Chief Executive Officer and Interim Chief Medical Officer of CTI BioPharma Corp. ("CTI BioPharma") and as a member of its board of directors from March 2017 until June 2023. He is a physician and experienced biopharmaceutical industry leader with extensive expertise in corporate strategic operations and governance, investor relations and financing; U.S. and EU regulatory engagement; and medical affairs and hematology and oncology research. Prior to CTI BioPharma, Dr. Craig worked as an independent consultant providing strategic and operational advice and support to CTI BioPharma and other hematology/oncology biotechnology companies since 2016. Prior to consulting, Dr. Craig was Chief Medical Officer and Executive Vice President of Development of Sunesis Pharmaceuticals, a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers, from 2012 to 2016. From 2008 to 2012, Dr. Craig was Chief Medical Officer and Senior Vice President of Chemgenex Pharmaceuticals Ltd, a biotechnology company which was acquired by Cephalon/Teva Pharmaceuticals in 2011. He also served as a Product Development Reviewer for the Cancer Prevention Research Institute of Texas. Dr. Craig has been a member of the board of directors of Stratus Therapeutics since August 2024. Dr. Craig earned his Medical Degree from Charing Cross and Westminster Medical School, University of London, a Ph.D. in Molecular Oncology from Leeds University in the U.K. and an M.B.A. from The Open University Business School (U.K.). Dr. Craig completed post-graduate training in Paediatrics, Neonatology and Paediatric Oncology and is a Member of both the Royal College of Physicians (London) and the Royal College of Paediatrics and Child Health.- Adam Raymond Craig，最近于2024年8月至2025年3月担任Stratus Therapeutics，Inc.（“Stratus Therapeutics”，原名Garuda Therapeutics，Inc.）的临时总裁兼首席执行官。他还曾担任CTI BioPharma Corp.（“CTI BioPharma”）的总裁、首席执行官兼临时首席医疗官，并于2017年3月至2023年6月期间担任其董事会成员。他是一名医生和经验丰富的生物制药行业领导者，在企业战略运营和治理、投资者关系和融资；美国和欧盟监管参与；以及医疗事务和血液学和肿瘤学研究方面拥有广泛的专业知识。在加入CTI BioPharma之前，Craig博士自2016年起担任独立顾问，为CTI BioPharma和其他血液学/肿瘤学生物技术公司提供战略和运营建议及支持。在咨询之前，Craig博士曾于2012年至2016年担任Sunesis Pharmaceuticals的首席医疗官和开发执行副总裁，该公司是一家生物制药公司，开发用于治疗血液和实体癌的新型靶向抑制剂。从2008年到2012年，克雷格博士担任Chemgenex Pharmaceuticals Ltd的首席医疗官和高级副总裁，该公司是一家生物技术公司，于2011年被Cephalon/Teva Pharmaceuticals收购。他还曾担任德克萨斯州癌症预防研究所的产品开发审评员。自2024年8月以来，克雷格博士一直是Stratus Therapeutics的董事会成员。克雷格博士在伦敦大学查林克罗斯和威斯敏斯特医学院获得医学学位，在英国利兹大学获得分子肿瘤学博士学位，在开放大学商学院（英国）获得工商管理硕士学位。Craig博士完成了儿科、新生儿科和儿科肿瘤学的研究生培训，并且是皇家内科医学院（伦敦）和皇家儿科和儿童健康学院的成员。
- Adam Raymond Craig,most recently served as the Interim President and Chief Executive Officer of Stratus Therapeutics, Inc. ("Stratus Therapeutics," formerly known as Garuda Therapeutics, Inc.) from August 2024 until March 2025. He also served as President, Chief Executive Officer and Interim Chief Medical Officer of CTI BioPharma Corp. ("CTI BioPharma") and as a member of its board of directors from March 2017 until June 2023. He is a physician and experienced biopharmaceutical industry leader with extensive expertise in corporate strategic operations and governance, investor relations and financing; U.S. and EU regulatory engagement; and medical affairs and hematology and oncology research. Prior to CTI BioPharma, Dr. Craig worked as an independent consultant providing strategic and operational advice and support to CTI BioPharma and other hematology/oncology biotechnology companies since 2016. Prior to consulting, Dr. Craig was Chief Medical Officer and Executive Vice President of Development of Sunesis Pharmaceuticals, a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers, from 2012 to 2016. From 2008 to 2012, Dr. Craig was Chief Medical Officer and Senior Vice President of Chemgenex Pharmaceuticals Ltd, a biotechnology company which was acquired by Cephalon/Teva Pharmaceuticals in 2011. He also served as a Product Development Reviewer for the Cancer Prevention Research Institute of Texas. Dr. Craig has been a member of the board of directors of Stratus Therapeutics since August 2024. Dr. Craig earned his Medical Degree from Charing Cross and Westminster Medical School, University of London, a Ph.D. in Molecular Oncology from Leeds University in the U.K. and an M.B.A. from The Open University Business School (U.K.). Dr. Craig completed post-graduate training in Paediatrics, Neonatology and Paediatric Oncology and is a Member of both the Royal College of Physicians (London) and the Royal College of Paediatrics and Child Health.
- John Volpone
John Volpone，是一家独立的生物制药顾问，自2023年6月起提供各种监管和商业战略咨询服务。此前，他曾在CTI BioPharma担任多个职务，包括最近于2021年9月至2023年6月担任执行副总裁兼参谋长，于2020年9月至2021年9月担任战略运营高级副总裁，于2017年9月至2020年9月担任战略运营–全球项目主管副总裁。他在战略商业伙伴关系、许可、监管参与和商业化方面是一位经验丰富的生物制药领导者。Volpone先生拥有西雅图大学的工商管理硕士学位和华盛顿大学的生物化学学士学位。
John Volpone,is an independent biopharma consultant providing a variety of regulatory and business strategy consulting services since June 2023. Previously, he served in various roles at CTI BioPharma, including most recently as Executive Vice President and Chief of Staff from September 2021 until June 2023, Senior Vice President, Strategic Operations from September 2020 until September 2021 and Vice President, Strategic Operations – Global Program Lead from September 2017 until September 2020. He is an experienced biopharmaceutical leader in strategic business partnerships, licensing, regulatory engagements and commercialization. Mr. Volpone holds an M.B.A. from Seattle University and a B.Sc. in Biochemistry from University of Washington.- John Volpone，是一家独立的生物制药顾问，自2023年6月起提供各种监管和商业战略咨询服务。此前，他曾在CTI BioPharma担任多个职务，包括最近于2021年9月至2023年6月担任执行副总裁兼参谋长，于2020年9月至2021年9月担任战略运营高级副总裁，于2017年9月至2020年9月担任战略运营–全球项目主管副总裁。他在战略商业伙伴关系、许可、监管参与和商业化方面是一位经验丰富的生物制药领导者。Volpone先生拥有西雅图大学的工商管理硕士学位和华盛顿大学的生物化学学士学位。
- John Volpone,is an independent biopharma consultant providing a variety of regulatory and business strategy consulting services since June 2023. Previously, he served in various roles at CTI BioPharma, including most recently as Executive Vice President and Chief of Staff from September 2021 until June 2023, Senior Vice President, Strategic Operations from September 2020 until September 2021 and Vice President, Strategic Operations – Global Program Lead from September 2017 until September 2020. He is an experienced biopharmaceutical leader in strategic business partnerships, licensing, regulatory engagements and commercialization. Mr. Volpone holds an M.B.A. from Seattle University and a B.Sc. in Biochemistry from University of Washington.